Buti M - Search Results

1

HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients.

Wong D, Littlejohn M, Yuen L, Jackson K, Mason H, Bayliss J, Rosenberg G, Gaggar A, Kitrinos K, Subramanian M, Marcellin P, Buti M, Janssen HLA, Gane E, Locarnini S, Thompson A, Revill PA. Wong D, et al. Among authors: buti m. Aliment Pharmacol Ther. 2018 Jan;47(1):114-122. doi: 10.1111/apt.14362. Epub 2017 Oct 11. Aliment Pharmacol Ther. 2018. PMID: 29023803 Clinical Trial.

2

Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.

Buti M, Olive G, Stalgis C, Esteban R, Guardi J. Buti M, et al. Dig Dis Sci. 2000 Apr;45(4):685-9. doi: 10.1023/a:1005479207106. Dig Dis Sci. 2000. PMID: 10759235

3

Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon.

San Miguel R, Mar J, Cabasés JM, Guillén-Grima F, Buti M. San Miguel R, et al. Among authors: buti m. Aliment Pharmacol Ther. 2003 Mar 15;17(6):765-73. doi: 10.1046/j.1365-2036.2003.01494.x. Aliment Pharmacol Ther. 2003. PMID: 12641498

4

A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C.

Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. Buti M, et al. Aliment Pharmacol Ther. 2003 Mar 1;17(5):687-94. doi: 10.1046/j.1365-2036.2003.01453.x. Aliment Pharmacol Ther. 2003. PMID: 12641518

5

Changes in different regions of hepatitis B virus gene in hepatitis B 'e' antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy.

Buti M, Jardi R, Rodriguez-Frias F, Valdes A, Schaper M, Esteban R, Guardia J. Buti M, et al. Aliment Pharmacol Ther. 2005 Jun 1;21(11):1349-56. doi: 10.1111/j.1365-2036.2005.02503.x. Aliment Pharmacol Ther. 2005. PMID: 15932365

6

Drugs in development for hepatitis B.

Buti M, Esteban R. Buti M, et al. Drugs. 2005;65(11):1451-60. doi: 10.2165/00003495-200565110-00001. Drugs. 2005. PMID: 16033287 Review.

7

Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B.

Buti M, Casado MA, Calleja JL, Salmerón J, Aguilar J, Rueda M, Esteban R. Buti M, et al. Aliment Pharmacol Ther. 2006 Feb 1;23(3):409-19. doi: 10.1111/j.1365-2036.2006.02767.x. Aliment Pharmacol Ther. 2006. PMID: 16423000

8

Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.

Crespo M, Esteban JI, Ribera E, Falco V, Sauleda S, Buti M, Esteban R, Guardia J, Ocaña I, Pahissa A. Crespo M, et al. Among authors: buti m. AIDS. 2007 Feb 19;21(4):477-81. doi: 10.1097/QAD.0b013e328012b5ba. AIDS. 2007. PMID: 17301566 Clinical Trial.

9

Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.

Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, Bonovas S, Esteban R. Buti M, et al. J Hepatol. 2007 Sep;47(3):366-72. doi: 10.1016/j.jhep.2007.04.011. Epub 2007 May 24. J Hepatol. 2007. PMID: 17561304

10

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.

Buster EH, Hansen BE, Buti M, Delwaide J, Niederau C, Michielsen PP, Flisiak R, Zondervan PE, Schalm SW, Janssen HL; HBV 99-01 Study Group. Buster EH, et al. Among authors: buti m. Hepatology. 2007 Aug;46(2):388-94. doi: 10.1002/hep.21723. Hepatology. 2007. PMID: 17604363 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

658 results

Search Page

Filters